Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.
AUTOR(ES)
Wise, R
RESUMO
The pharmacology of cefotaxime and the metabolite desacetyl cefotaxime was studied in 40 patients with various degrees of renal and hepatic failure who received 0.5 or 1 g of cefotaxime intravenously. Patients with severe renal impairment (creatinine clearance, 3 to 10 ml/min) had a cefotaxime serum half-life of 2.6 h and desacetyl cefotaxime serum half-life of 10.0 h. The equivalent figures were 1.0 and 1.5 h, respectively, in subjects with normal renal function. The presence of an acute coexisting illness together with severe renal impairment was associated with a further prolongation of the serum half-lives. Hepatic dysfunction was accompanied by a reduction in desacetyl metabolite formation. A reduction of cefotaxime dosing to 0.5 g twice a day would appear prudent when the creatinine clearance is 5 ml/min or less to avoid accumulation of the parent compound and the metabolite.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=181470Documentos Relacionados
- Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.
- Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
- Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
- Pharmacokinetics of cefotaxime and desacetylcefotaxime in patients with liver disease.
- Clinical pharmacology of moxalactam in patients with malignant disease.
